Diabetic mesenchymal stem cells are ineffective for improving limb ischemia due
to their impaired angiogenic capability.
Authors Kim H, Han JW, Lee JY, Choi YJ, Sohn YD, Song M, Yoon YS
Submitted By Submitted Externally on 8/5/2014
Status Published
Journal Cell transplantation
Year 2014
Date Published 7/8/2014
Volume : Pages Not Specified : Not Specified
PubMed Reference 25008576
Abstract The purpose of this study was to investigate the effects of diabetes on
mesenchymal stem cells (MSCs) in terms of their angiogenic and therapeutic
potential for repairing tissue ischemia. We culture-isolated MSCs from
streptozotocin-induced diabetic rats (D-MSCs) and compared their proliferation,
differentiation, and angiogenic effects with those from normal rats (N-MSCs).
The angiogenic effects of MSCs were evaluated by real-time RT-PCR, in vitro tube
formation assay, and transplantation of the MSCs into a hindlimb ischemia model
followed by laser Doppler perfusion imaging. The number of MSCs derived from
diabetic rats was smaller and their proliferation rate was slower than N-MSCs.
Upon induction of differentiation, the osteogenic and adipogenic differentiation
of D-MSCs were aberrant compared to N-MSCs. The expression of angiogenic factors
was lower in D-MSCs than N-MSCs. D-MSCs co-cultured with endothelial cells
resulted in decreased tube formation compared to N-MSCs. D-MSCs were ineffective
to improve hindlimb ischemia and showed lower capillary density and angiogenic
gene expression in ischemic limbs than N-MSCs. D-MSCs have defective
proliferation and angiogenic activities and are ineffective for repairing
hindlimb ischemia. Newer measures are needed before MSCs can be employed as a
source for autologous cell therapy.


Investigators with authorship
NameInstitution
Young-sup YoonEmory University

Complications